Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Diabetes, Metabolic Syndrome and Obesity is Scopus-indexed (Q2, CiteScore 5.3), WoS SCIE, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1178-7007Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Internal Medicine | 59 / 179 | 67th | Q2 |
| Pharmacology | 128 / 328 | 61st | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 5.3.
Diabetes, Metabolic Syndrome and Obesity is Q2 in Internal Medicine (rank 59 of 179) and Q2 in Pharmacology (rank 128 of 328), by CiteScore 2025.
Diabetes, Metabolic Syndrome and Obesity is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.3, which places it in quartile Q2 at the 67th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.890, quartile Q2, with an H-index of 80.
The publisher lists an article processing charge of about US$2,836 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Diabetes, Metabolic Syndrome and Obesity is published by Dove Medical Press Ltd. Its ISSN is 1178-7007.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Diabetes, Metabolic Syndrome and Obesity has an h-index of 99 and a 2-year mean of 3.63 citations per paper (OpenAlex). Its Scopus CiteScore is 5.3, quartile Q2. On 2-year citations it ranks #37 of 172 Scopus journals in Internal Medicine.
Diabetes, Metabolic Syndrome and Obesity published 389 papers in 2025; its busiest recent year was 2020 with 489. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (71.7%), Indonesia (3%) and Saudi Arabia (2.4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (2.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.